Razoxane in the treatment of psoriatic patients resistant to or intolerant of PUVA, methotrexate and etretinate
Mom, A.; Aresca, S.; Fuente, G.; Pecorini, V.; Pellerano, G.; Perez, V.
Acta Dermato-Venereologica 62(4): 357-358
1982
ISSN/ISBN: 0001-5555 PMID: 6183878 Document Number: 196808
Thirty-six psoriatic patients resistant to or intolerant to PUVA, methotrexate and/or etretinate were treated with razoxane (ICRF 159) and EDTA derivative with antimitotic effects. The drug is highly effective in cutaneous and arthropathic psoriasis. Razoxane is well tolerated and appears to be free of hepatotoxicity. Besides some nausea and lethargy, 60% of the patients showed neutropenia, which can be easily controlled.
Document emailed within 1 workday
Related Documents
Brun, P.; Baran, R.; Juhlin, L. 1985: Acropustulosis resistant to combined etretinate and PUVA therapy Annales de Dermatologie et de Venereologie 112(8): 611-612Castel, T.; Castro, J.; Lecha, M.; Mascaró, J.M. 1986: Unusual side effects in patients with psoriatic erythroderma treated with etretinate (RO 10-9359) Medicina Cutanea Ibero-Latino-Americana 14(2): 83-86
Rosdahl, I.K.; Swanbeck, G. 1980: Effects of PUVA on the epidermal melanocyte population in psoriatic patients Acta Dermato-Venereologica 60(1): 21-26
Vázqvez-López, F.; Pérez-Oliva, N. 1996: Transient hyperpigmentation after calcipotriol ointment and PUVA therapy in psoriatic patients Acta Dermato-Venereologica 76(5): 400
Borroni, G.; Brazzelli, V.; Fietta, A.; Gatti, M.; Bellosta, M.; Vignati, G.; Zaccone, C.; Berardesca, E.; Rabbiosi, G. 1989: Effects of medium-term PUVA therapy on peripheral T-lymphocyte subsets in psoriatic patients Acta Dermato-Venereologica. Supplementum 146: 125-129
Chodorowska, G.; Czelej, D.; Juszkiewicz-Borowiec, M.; Pietrzak, A.; Wojnowska, D.; Krasowska, D. 1999: Selected cytokines and acute phase proteins in psoriatic patients treated with cyclosporin A or Re-PUVA methods Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 54: 173-180
Lauharanta, J.; Salo, O.; Kanerva, L.; Lassus, A. 1982: The effect of etretinate on fibronectin in psoriatic skin Acta Dermato-Venereologica 62(4): 358-361
Moldenhauer, E.; Dabels, J.; Diwok, K.; Leithäuser, W.; Nowotny, P. 1973: Incidence of liver diseases in psoriatic patients with special reference to methotrexate therapy Dermatologische Monatschrift 159(3): 242-248
Belzunegui, J.; Intxausti, J.J.; De Dios, J.R.; López-Domínguez, L.; Queiro, R.; González, C.; Figueroa, M. 2001: Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate Clinical and Experimental Rheumatology 19(6): 727-730
Lubach, D.; Kietzmann, M. 1988: Effects of treatment with dithranol, etretinate and a combination of dithranol and etretinate on epidermal metabolism and histology. Mouse tail assay Arzneimittel-Forschung 38(8): 1167-1170
Cervantes, F.; Hernández-Boluda, J-Carlos.; Steegmann, J-Luis.; Conde, E.; Alvarez-Larrán, A.; López-Jiménez, J.; Osorio, S.; Villalón, Lía.; Camós, M.; García-Conde, J.; Odriozola, Jús. 2003: Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients Haematologica 88(10): 1117-1122
Chlebowski, R.T.; Pugh, R.P.; Bull, F.; McCracken, J.; Glass, A.; Bateman, J.R. 1984: Concomitant razoxane and doxorubicin treatment on a weekly schedule Cancer Treatment Reports 68(7-8): 1035-1037
McGirr, E.E.; Browne, C.D.; Champion, G.D.; Day, R.O.; Sambrook, P.N. 1984: Aurothioglucose in rheumatoid arthritis. Outcome of treatment in patients intolerant of sodium aurothiomalate Medical Journal of Australia 141(6): 349-351
Modrzyński, M.; Zawisza, E.; Rapiejko, P. 2002: Zafirlukast in treatment of nasal polyps in patients with aspirin intolerant bronchial asthma--preliminary report Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego 12(69): 224-227
Palungwachira, P.; Palungwachira, P.; Laohathai, P. 1998: Methotrexate induced pericarditis and pericardial effusion in psoriatic patient Journal of the Medical Association of Thailand 81(2): 141-145
Zhang, G.-L.; Huang, F.; Zhang, J.-L.; Li, X.-F. 2009: A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis Zhonghua Nei Ke Za Zhi 48(7): 570-574
Ward, M.A.; Artunduaga, G.; Thompson, K.P.; Wilson, L.A.; Stulting, R.D. 1995: Phototherapeutic keratectomy for the treatment of nodular subepithelial corneal scars in patients with keratoconus who are contact lens intolerant Clao Journal: Official Publication of the Contact Lens Association of Ophthalmologists Inc 21(2): 130-132
Ferraccioli, G.; Casatta, L.; Bartoli, E. 1996: Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy Journal of Rheumatology 23(9): 1539-1542
Agarwal, K.Kumar.; Nath, A.Kumar.; Thappa, D.Mohan. 2008: Methotrexate toxicity presenting as ulceration of psoriatic plaques: a report of two cases Indian Journal of Dermatology Venereology and Leprology 74(5): 481-484
Leeb, B.; Dunky, A.; Ogris, E.; Wohanka, A.; Schenk, G.; Gaismayer, K.; Eberl, R. 1989: Methotrexate serum-level determinations during low-dose therapy of rheumatoid and psoriatic arthritis International Journal of Clinical Pharmacology Research 9(3): 209-215